标题
Everolimus in colorectal cancer
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 4, Pages 505-513
出版商
Informa Healthcare
发表日期
2013-02-14
DOI
10.1517/14656566.2013.770473
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
- (2012) Gordana Vlahovic et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Targeting mTOR Pathways in Human Malignancies
- (2012) Angelica Fasolo et al. CURRENT PHARMACEUTICAL DESIGN
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
- (2012) C. Renner et al. HAEMATOLOGICA
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
- (2011) Arkaitz Carracedo et al. CELL CYCLE
- Current and future directions in mammalian target of rapamycin inhibitors development
- (2011) Angelica Fasolo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer
- (2011) I. Altomare et al. ONCOLOGIST
- Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo
- (2010) Terry OʼReilly et al. ANTI-CANCER DRUGS
- The role of mTORC1 pathway in intestinal tumorigenesis
- (2010) Teruaki Fujishita et al. CELL CYCLE
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
- (2010) S. S. Agarwala et al. ONCOLOGIST
- Persistent effects of everolimus on strength of experimental wounds in intestine and fascia
- (2010) Martine C. M. Willems et al. WOUND REPAIR AND REGENERATION
- Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer
- (2009) Yan-Jie Zhang et al. CANCER INVESTIGATION
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Pathways mediating VEGF-independent tumor angiogenesis
- (2009) Napoleone Ferrara CYTOKINE & GROWTH FACTOR REVIEWS
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
- (2008) R Bianco et al. BRITISH JOURNAL OF CANCER
- mTOR inhibitors in the treatment of cancer
- (2008) Angelica Fasolo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started